[从神经学的角度来看,使用莱维体治疗痴呆症]
1Medical Center for Dementia, Juntendo University Hospital.
Brain and nerve = Shinkei kenkyu no shinpo
|June 16, 2025
概括
患有勒维体 (DLB) 痴呆症可能会导致显著的行为症状. 有效的管理涉及药物,托儿所和神经病学家和精神病学家的协作护理的结合.
科学领域:
- 神经学 神经学
- 老年病的医生 老年病的医生
- 精神病学是一个精神病学.
背景情况:
- 患有莱维体的痴呆症 (DLB) 具有认知衰退和行为障碍的特征.
- 行为和心理症状是常见的,并且可以具有挑战性来管理.
- 神经学和精神病学干预对于全面的DLB护理至关重要.
研究的目的:
- 要突出管理的行为和心理症状在痴呆症的莱维体.
- 为了说明神经病学和精神病学在治疗DLB患者中的作用.
- 提交展示治疗结果的案例研究.
主要方法:
- 对两名患有DLB的老年女性患者的病例报告分析.
- 审查治疗策略,包括药物治疗 (多尼佩西尔,美曼丁) 和非药物干预 (日托).
- 检查神经病学和精神病学的转诊模式.
主要成果:
- 药理疗法在控制DLB症状方面表现出有效性.
- 一位患者的日托中心开始导致症状改善.
- 神经学家和精神病学家在DLB管理中发挥着互补的作用.
结论:
- 涉及神经病学家和精神病学家的综合护理对于最佳的DLB患者结果至关重要.
- 行为和心理症状需要迅速和专业的干预.
- 包括药物治疗和支持性护理在内的多学科方法是管理DLB的关键.
相关概念视频
Parkinson's Disease: Overview
723
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
723
Parkinson's Disease: Treatment
391
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
391
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Dementia
182
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
182
Alzheimer's Disease: Overview
686
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
686
Neural Regulation
40.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.4K


